WO2025202938 - PHARMACEUTICAL COMPOSITION COMPRISING A CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF ACUTE MIGRAINE
National phase entry is expected:
Publication Number
WO/2025/202938
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053209
International Filing Date
26.03.2025
Title **
[English]
PHARMACEUTICAL COMPOSITION COMPRISING A CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF ACUTE MIGRAINE
[French]
COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE AIGUË
Applicants **
NUVIE BIO, INC.
Inventors
NEYER, Gebhard
VERLANDER, Michael Stephen
FINEMAN, Mark Stephen
CADY, Roger Kenneth
RIVIERE, Pierre Jean-Marie
Priority Data
63/570,030
26.03.2024
US
24174797.1
08.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2106 | |
| EPO | Filing, Examination, Granting | 8644 | |
| Japan | Filing, Examination, Granting | 2210 | |
| South Korea | Filing, Examination, Granting | 2137 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,837
Contact Us
Abstract[English]
The present invention relates to a calcitonin gene-related peptide (CGRP) receptor antagonist of formula (I) or a or equivalent net peptide weight of a pharmaceutically active salt thereof, namely AXN-001, which is also known as FE 205030 A pharmaceutical composition comprising AXN-001 can be used in the treatment of acute migraine.[French]
La présente invention concerne un antagoniste du récepteur du peptide lié au gène de la calcitonine (CGRP) de formule (I) ou le poids peptidique net équivalent d'un sel pharmaceutiquement actif de celui-ci, à savoir AXN-001, qui est également connu sous le nom de FE 205030. Une composition pharmaceutique comprenant AXN-001 peut être utilisée dans le traitement de la migraine aiguë.